Sorrento Therapeutics, Inc.
US ˙ OTCPK ˙ US83587F2020

Introduction

This page provides a comprehensive analysis of the known insider trading history of Jaisim Shah. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Jaisim Shah has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:SCLX / Scilex Holding Company See Remarks, Director 139,333
US:SRNE / Sorrento Therapeutics, Inc. Director 250,000
US:69329YAE4 / PDL BioPharma, Inc. Bond 2.875% SR VP, Mkt & Business Affairs 13,940
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Jaisim Shah. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases SRNE / Sorrento Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in SRNE / Sorrento Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2017-06-15 SRNE SHAH JAISIM 10,002 1.7900 10,002 1.7900 17,904 258 9.95 81,617 455.88
2017-02-03 SRNE SHAH JAISIM 10,000 5.1500 10,000 5.1500 51,500
2015-08-03 SRNE SHAH JAISIM 27,189 11.5000 27,189 11.5000 312,674
2013-11-25 SRNE SHAH JAISIM 1,000 8.6500 1,000 8.6500 8,650
2013-11-19 SRNE SHAH JAISIM 1,000 9.0000 1,000 9.0000 9,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SRNE / Sorrento Therapeutics, Inc. Insider Trades
Insider Sales SRNE / Sorrento Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in SRNE / Sorrento Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SRNE / Sorrento Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Jaisim Shah as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-12-18 2024-12-18 4 SCLX Scilex Holding Co
Common Stock
P - Purchase 30,000 139,333 27.44 0.46 13,800 64,093
2024-10-29 2024-10-29 4 SCLX Scilex Holding Co
Common Stock
P - Purchase 32,000 109,333 41.38 0.99 31,670 108,207
2024-10-17 2024-10-16 4 SCLX Scilex Holding Co
Common Stock
P - Purchase 30,000 77,333 63.38 0.99 29,751 76,691
2024-06-20 2024-06-20 4 SCLX Scilex Holding Co
Common Stock
M - Exercise 14,000 47,333 42.00 1.73 24,220 81,886
2024-06-14 2024-06-14 4 SCLX Scilex Holding Co
Common Stock
M - Exercise 33,333 33,333 1.41 47,000 47,000
2024-05-17 2024-05-17 4 SCLX Scilex Holding Co
Common Stock
P - Purchase 56,939 155,882 57.55 0.92 52,099 142,632
2024-05-17 2024-05-16 4 SCLX Scilex Holding Co
Common Stock
P - Purchase 83,061 98,943 522.99 0.84 69,846 83,201
2021-08-30 2021-08-30 4 SRNE Sorrento Therapeutics, Inc.
Stock option (right to buy)
A - Award 250,000 250,000
2020-06-15 2020-06-15 4 SRNE Sorrento Therapeutics, Inc.
Stock Options
A - Award 100,000 100,000
2019-04-23 2019-04-19 4 SRNE Sorrento Therapeutics, Inc.
Stock Options
A - Award 70,000 70,000
2018-11-27 2018-11-26 4 SRNE Sorrento Therapeutics, Inc.
Stock Options
A - Award 35,000 35,000
2017-09-18 2017-09-15 4/A SRNE Sorrento Therapeutics, Inc.
Stock Options
A - Award 35,000 35,000
2017-09-15 2017-09-15 4 SRNE Sorrento Therapeutics, Inc.
Stock Options
A - Award 35,000 35,000
2017-06-15 2017-06-15 4 SRNE Sorrento Therapeutics, Inc.
Common Stock
P - Purchase 10,002 112,633 9.75 1.79 17,904 201,613
2017-02-03 2017-02-03 4 SRNE Sorrento Therapeutics, Inc.
Common Stock
P - Purchase 10,000 102,631 10.80 5.15 51,500 528,550
2016-07-12 2016-07-11 4 SRNE Sorrento Therapeutics, Inc.
Stock Options
A - Award 35,000 305,000 12.96
2015-08-05 2015-08-03 4 SRNE Sorrento Therapeutics, Inc.
Common Stock
P - Purchase 27,189 92,631 41.55 11.50 312,674 1,065,256
2015-06-08 2015-06-04 4 SRNE Sorrento Therapeutics, Inc.
Stock Options
A - Award 25,000 270,000 10.20
2015-02-26 2015-02-24 4 SRNE Sorrento Therapeutics, Inc.
Stock Options
A - Award 80,000 245,000 48.48
2014-09-22 2014-09-18 4 SRNE Sorrento Therapeutics, Inc.
Stock Options
A - Award 25,000 165,000 17.86
2013-11-26 2013-11-25 4 SRNE Sorrento Therapeutics, Inc.
Common Stock
P - Purchase 1,000 65,442 1.55 8.65 8,650 566,073
2013-11-20 2013-11-19 4 SRNE Sorrento Therapeutics, Inc.
Common Stock
P - Purchase 1,000 64,442 1.58 9.00 9,000 579,978
2013-10-31 2013-10-29 4 SRNE Sorrento Therapeutics, Inc.
Stock Options
A - Award 80,000 140,000 133.33
2013-09-20 3 SRNE Sorrento Therapeutics, Inc.
Common Stock
0
2007-04-17 2007-04-13 4 PDLI PDL BIOPHARMA, INC.
Common Stock
S - Sale X -1,747 13,940 -11.14 24.00 -41,928 334,560
2007-04-17 2007-04-13 4 PDLI PDL BIOPHARMA, INC.
Common Stock
M - Exercise 1,747 15,687 12.53 12.29 21,471 192,793
2007-04-17 2007-04-13 4 PDLI PDL BIOPHARMA, INC.
Common Stock
S - Sale X -6,875 13,940 -33.03 24.00 -165,000 334,560
2007-04-17 2007-04-13 4 PDLI PDL BIOPHARMA, INC.
Common Stock
M - Exercise 6,875 20,815 49.32 9.00 61,875 187,335
2007-04-17 2007-04-13 4 PDLI PDL BIOPHARMA, INC.
Common Stock
S - Sale X -1,378 13,940 -9.00 24.00 -33,072 334,560
2007-04-17 2007-04-13 4 PDLI PDL BIOPHARMA, INC.
Common Stock
M - Exercise 1,378 15,318 9.89 8.55 11,782 130,969
2007-04-17 2007-04-11 4 PDLI PDL BIOPHARMA, INC.
Common Stock
S - Sale X -5,497 13,940 -28.28 23.00 -126,431 320,620
2007-04-17 2007-04-11 4 PDLI PDL BIOPHARMA, INC.
Common Stock
M - Exercise 5,497 19,437 39.43 8.55 46,999 166,186
2007-04-17 2007-04-11 4 PDLI PDL BIOPHARMA, INC.
Common Stock
S - Sale X -4,583 13,940 -24.74 23.00 -105,409 320,620
2007-04-17 2007-04-11 4 PDLI PDL BIOPHARMA, INC.
Common Stock
M - Exercise 4,583 18,523 32.88 7.83 35,885 145,035
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)